Maladaptive epigenetic control of MUC5B transcription in pulmonary fibrosis
肺纤维化中 MUC5B 转录的适应不良表观遗传控制
基本信息
- 批准号:10627598
- 负责人:
- 金额:$ 50.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAddressAgingAreaBindingBronchiolesCell Culture TechniquesCell Differentiation processCellsChIP-seqChromatinCollaborationsCuesDNADataDiseaseDistalEnhancersEpigenetic ProcessEpithelial CellsEpitheliumEtiologyEuropeanEventFamilyFibroblastsGene Expression RegulationGenetic TranscriptionGenomicsGenotypeHumanInjuryInvestigationMUC5B geneMalignant NeoplasmsMethodsModelingMolecularMusOdds RatioParticulatePathogenesisPhenotypePopulationProcessPulmonary FibrosisRNARegulationResponse ElementsRiskRisk FactorsRoleSamplingSiteSmokingTerminal BronchioleTestingTissue SampleTranscriptTranscriptional RegulationWorkXBP1 geneactivating transcription factorairway epitheliumbiological adaptation to stresschromatin remodelingendoplasmic reticulum stressepigenetic regulationgenome-widehuman modelhuman tissueidiopathic pulmonary fibrosisknock-downlung injurymortalitymouse modelnew therapeutic targetoverexpressionprogramsrecruitresponseresponse to injurytranscription factor
项目摘要
Project Summary
In this project, we will define epigenetic and transcriptional mechanisms that result in increased MUC5B
expression, distal airway epithelial abnormalities, and associated fibroproliferative phenotypes. Idiopathic
pulmonary fibrosis (IPF) has a 5-year mortality rate surpassing many cancers. The G-to-T transversion,
rs35705950, is the most potent known risk factor for developing IPF and is located ~ 3 kb upstream of the
MUC5B gene. This -3 kb region regulates MUC5B expression, which is increased in IPF, especially in terminal
bronchiole-like regions. Bronchioles are a primary site of IPF pathogenesis and feature aberrant epithelial
differentiation in disease, promoting local recruitment and activation of fibroblasts. Although rs35705950 and
MUC5B are key players in IPF pathogenesis, rs35705950 alone is not sufficient to cause IPF, and we don’t
fully understand how MUC5B and rs35705950 promote IPF pathogenesis. Our proposal is based on a two- hit
hypothesis that addresses these gaps. We hypothesize that MUC5B overexpression, potentiated by epigenetic
changes, primes the bronchiolar epithelium such that a second injurious hit results in aberrant epigenetic
regulation, detrimental ER stress and fibroblast activation. Three Aims address this hypothesis. In Aim 1, we
will determine molecular control of MUC5B transcription in proximal and distal airway epithelia from unaffected
and IPF subjects. This work extends our preliminary data on -3 kb MUC5B enhancer function, and we will
specifically test whether the pioneer transcription factor, FOXA2, induces chromatin remodeling, enhancer
RNA transcription and MUC5B expression through methods such as ChIP and factor knockdown. In Aim 2 we
will identify epigenetic and transcription factor mechanisms that drive abnormal distal airway epithelial cell
differentiation in relationship to MUC5B expression and genotypes in IPF. Aim 2 is motivated by our data
implicating important roles in IPF for two transcription factors involved in normal airway epithelial differentiation,
EHF and GRHL2. Our methods in Aim 2 will include ATAC-seq, nascent transcript sequencing, knockdown
and ChIP to define mechanistic roles for these factors in IPF, with extension of our findings into human
samples and cells from Muc5b overexpressing mice. In Aim 3, we will investigate the role of airway epithelial
epigenetics and MUC5B expression on transcriptional control of ER stress and fibroblast activation in IPF. Aim
3 builds on our data supporting an epigenetic mechanism in detrimental ER stress responses where IPF-
derived cells direct the master ER stress regulator, XBP1(S) to interact with open chromatin at motifs for the
ATF family of transcription factors. We will extend on these findings through applying ATAC-seq and ChIP-seq
to study XBP1(S) genomic occupancy and ATF4 crosstalk in IPF-derived human airway epithelial cells. We will
also study fibroblast epigenetics in relationship to airway epithelial abnormalities in IPF. Taken together, these
studies will advance our molecular understanding of transcriptional control in IPF pathogenesis and identify
new targets for restoring distal airway epithelial function in this devastating disease.
项目概要
在这个项目中,我们将定义导致 MUC5B 增加的表观遗传和转录机制
表达、远端气道上皮异常和相关的纤维增殖表型。特发性
肺纤维化(IPF)的 5 年死亡率超过许多癌症。 G 到 T 的颠换,
rs35705950 是已知的最有效的 IPF 风险因素,位于 rs35705950 上游约 3 kb 处。
MUC5B 基因。该 -3 kb 区域调节 MUC5B 表达,该表达在 IPF 中增加,尤其是在终末期
细支气管样区域。细支气管是 IPF 发病机制的主要部位,具有异常的上皮细胞特征
疾病分化,促进成纤维细胞的局部募集和激活。虽然 rs35705950 和
MUC5B 是 IPF 发病机制的关键参与者,单独的 rs35705950 不足以引起 IPF,我们不认为
充分了解MUC5B和rs35705950如何促进IPF发病机制。我们的建议是基于两次打击
解决这些差距的假设。我们假设表观遗传增强了 MUC5B 的过度表达
变化,启动细支气管上皮,从而导致第二次伤害性打击导致异常的表观遗传
调节、有害的 ER 应激和成纤维细胞激活。三个目标解决了这一假设。在目标 1 中,我们
将确定未受影响的近端和远端气道上皮中 MUC5B 转录的分子控制
和 IPF 科目。这项工作扩展了我们关于 -3 kb MUC5B 增强子功能的初步数据,我们将
专门测试先锋转录因子 FOXA2 是否诱导染色质重塑、增强子
通过 ChIP 和因子敲低等方法进行 RNA 转录和 MUC5B 表达。在目标 2 中,我们
将识别驱动异常远端气道上皮细胞的表观遗传和转录因子机制
IPF 中与 MUC5B 表达和基因型相关的分化。目标 2 是由我们的数据推动的
暗示两种参与正常气道上皮分化的转录因子在 IPF 中发挥重要作用,
EHF 和 GRHL2。我们的目标 2 方法将包括 ATAC-seq、新生转录本测序、敲除
和 ChIP 来定义这些因素在 IPF 中的机制作用,并将我们的发现扩展到人类
来自 Muc5b 过表达小鼠的样本和细胞。在目标 3 中,我们将研究气道上皮细胞的作用
表观遗传学和 MUC5B 表达对 IPF 中 ER 应激和成纤维细胞活化转录控制的影响。目的
3 基于我们的数据,支持有害 ER 应激反应的表观遗传机制,其中 IPF-
衍生细胞指导主 ER 应激调节因子 XBP1(S) 与开放染色质的基序相互作用
ATF 转录因子家族。我们将通过应用 ATAC-seq 和 ChIP-seq 来扩展这些发现
研究 IPF 衍生的人气道上皮细胞中 XBP1(S) 基因组占据和 ATF4 串扰。我们将
还研究了与 IPF 气道上皮异常相关的成纤维细胞表观遗传学。综合起来,这些
研究将促进我们对 IPF 发病机制中转录控制的分子理解,并确定
在这种毁灭性疾病中恢复远端气道上皮功能的新目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANTHONY N GERBER其他文献
ANTHONY N GERBER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANTHONY N GERBER', 18)}}的其他基金
Aspen Lung Conference: Asthma: Pathogenesis, Phenotypes, Therapies and Gaps
阿斯彭肺部会议:哮喘:发病机制、表型、治疗方法和差距
- 批准号:
10680832 - 财政年份:2023
- 资助金额:
$ 50.99万 - 项目类别:
Mechanisms and Consequences of Gene Induction by Glucocorticoids in Airway Smooth Muscle
糖皮质激素在气道平滑肌中基因诱导的机制和后果
- 批准号:
10446915 - 财政年份:2012
- 资助金额:
$ 50.99万 - 项目类别:
Role of Klf15 in airway smooth muscle and the response to glucocorticoids
Klf15 在气道平滑肌中的作用以及对糖皮质激素的反应
- 批准号:
8459449 - 财政年份:2012
- 资助金额:
$ 50.99万 - 项目类别:
Role of Klf15 in airway smooth muscle and the response to glucocorticoids
Klf15 在气道平滑肌中的作用及对糖皮质激素的反应
- 批准号:
8645718 - 财政年份:2012
- 资助金额:
$ 50.99万 - 项目类别:
Mechanisms and Consequences of Gene Induction by Glucocorticoids in Airway Smooth Muscle
糖皮质激素在气道平滑肌中基因诱导的机制和后果
- 批准号:
10641892 - 财政年份:2012
- 资助金额:
$ 50.99万 - 项目类别:
Role of Klf15 in airway smooth muscle and the response to glucocorticoids
Klf15 在气道平滑肌中的作用及对糖皮质激素的反应
- 批准号:
8826799 - 财政年份:2012
- 资助金额:
$ 50.99万 - 项目类别:
Role of Klf15 in airway smooth muscle and the response to glucocorticoids
Klf15 在气道平滑肌中的作用以及对糖皮质激素的反应
- 批准号:
8298027 - 财政年份:2012
- 资助金额:
$ 50.99万 - 项目类别:
Gli1 in murine lung development and differentiation
Gli1 在小鼠肺发育和分化中的作用
- 批准号:
7459012 - 财政年份:2005
- 资助金额:
$ 50.99万 - 项目类别:
Gli1 in murine lung development and differentiation
Gli1 在小鼠肺发育和分化中的作用
- 批准号:
6956616 - 财政年份:2005
- 资助金额:
$ 50.99万 - 项目类别:
Gli1 in murine lung development and differentiation
Gli1 在小鼠肺发育和分化中的作用
- 批准号:
7254125 - 财政年份:2005
- 资助金额:
$ 50.99万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 50.99万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 50.99万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 50.99万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 50.99万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 50.99万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 50.99万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 50.99万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 50.99万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 50.99万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 50.99万 - 项目类别:
Research Grant